platoseedplatoseed
AI Diagnosis of Heart Disease
At InVision, we use AI to help streamline the interpretation of ultrasounds and identify diseases that may have been missed by human readers. Our models have been tightly integrated into the clinical workflow to allow easy usage by clinicians. Our work has previously been peer-reviewed and published in several top medical venues, including Nature (2020), Nature Medicine (2021), Lancet Digital Health (2021), JAMA Cardiology (2022). Results from our blinded and randomized clinical trial on evaluating cardiac function have also been recently presented as a Late Breaking Clinical Trial at the European Society of Cardiology.
InVision Medical Technology provides FDA-cleared AI tools for echocardiography to streamline interpretation, standardize measurements, and surface undiagnosed cardiac conditions. The platform integrates with existing imaging workflows and is backed by extensive academic research and clinical evidence.
The product is a platform offering FDA 510(k) cleared AI algorithms for echocardiography, including Precision LVEF for automated left ventricular ejection fraction assessment and Precision Cardiac Amyloid for AI-based screening of amyloidosis. It deploys alongside existing PACS, Epic EHR, and reporting platforms, using DICOM-native post-processing with no new hardware. The roadmap includes additional modules such as Precision Cirrhosis and Precision Reporting, powered by a foundation model (EchoNet-based) and validated across multiple health systems. Evidence includes Nature and JAMA Cardiology publications and a blinded randomized trial demonstrating time savings and improved precision. Reimbursement CPT code 0932T supports AI-assisted echocardiographic evaluation for heart failure symptoms.
Who it’s for: Health systems and cardiology departments performing routine echocardiography, including echo labs seeking reproducible measurements, undiagnosed cardiac conditions, and integration with existing imaging and EHR workflows.
Evidence-backed with multiple peer-reviewed publications; FDA clearance; active clinical deployment and a documented roadmap for expansion
MD 2014, UCSF Internal Medicine Residency 2017, Stanford Cardiology Fellowship 2020, Stanford Cardiologist, Cedars Sinai Medical Center
PhD Computer Science 2022, Stanford University BS Computer Science 2015, California Institute of Technology
InVision develops AI to streamline the interpretation of heart ultrasounds and identify undiagnosed disease.
InVision develops AI tools to streamline interpretation of heart ultrasounds and identify undiagnosed heart disease. They announce integration into clinical workflow, ongoing blinded randomized trial in cardiology, and plans for FDA clearance and clinical trials for screening various cardiac conditions.
From the original launch (Aug 2022) — may be outdated.
Formerly “EchoNet” · why startups rename →
Automation for dental clinics and insurance companies.
A new way of seeing inside the human body.
